Latest News

Listen: Drug industry infighting, the human side of genetic medicine, and a big year for the microbiome

Can biopharma police itself? Who decides whether something’s a disease or a difference? And will fecal matter ever become a drug?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, our colleague Ed Silverman joins us to explain the story of Belcher Pharmaceuticals, a company that raised the price on a decades-old medicine and irked its peers in the process. Then, cardiologist Ethan Weiss calls in to share a personal story about his daughter with albinism and how raising her has shaped his views on advances in genome editing and gene therapy. Later, STAT’s Kate Sheridan stops by to explain why the microbiome field is in for a make-or-break year. Finally, we embark on a lightning round, featuring Warren Buffett’s investments in biotech, Wall Street’s views on fish oil, and the latest prison sentence for a biopharma executive.

Read the rest…

Source link

Related posts

Proceedings of the 3rd BEAT-PCD Conference and 4th PCD Training School


One in three patients may experience side effects from ketamine infusions for pain management


Second HPV-related primary cancers common in survivors


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy